OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for RC207689L2V

CST6 (NM_001323) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type:	Lentiviral Particles
Product Name:	CST6 (NM_001323) Human Tagged ORF Clone Lentiviral Particle
Symbol:	CST6
Synonyms:	ECTD15
Mammalian Cell Selection:	None
Vector:	pLenti-C-mGFP (PS100071)
Tag:	mGFP
ACCN:	NM_001323
ORF Size:	447 bp
ORF Nucleotide Sequence:	The ORF insert of this clone is exactly the same as(RC207689).
OTI Disclaimer:	The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation:	This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
RefSeq:	NM_001323.2
RefSeq Size:	618 bp
RefSeq ORF:	450 bp
Locus ID:	1474
UniProt ID:	Q15828
Cytogenetics:	11q13.1
Protein Families:	Secreted Protein
MW:	16.5 kDa

View online »

Gene Summary: The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. This gene encodes a cystatin from the type 2 family, which is down-regulated in metastatic breast tumor cells as compared to primary tumor cells. Loss of expression is likely associated with the progression of a primary tumor to a metastatic phenotype. [provided by RefSeq, Jul 2008]